Hello Traders, It has been hot out and we are working on making it hotter with our updated REVERSE MERGER REPORT. We are the only newsletter providing 100% uncompensated alerts. Here is the merger report...
BPAC is on the verge of explosion and you are hearing about it here first!
Why we think BPAC is a ten bagger in the making:
*Very thinly traded and tiny O/S of less than 43 million shares.
*Proven products and major distribution channels already in place.
*The street has no idea this merger has taken place yet.
*There has not yet been an official press release.
*BPAC appears to be debt free.
8-K filed on July 2nd, 2012 in regards to the acquisition of Northstar consumer products LLC
The "Beaute de Maman" product line is currently offered at Target, CVS Pharmacy and Amazon.com
BPAC owns the rights to market the NCP products and the rights to acquire NCP as a wholly owned subsidiary. We like that one of the conditions is to remain fully reporting. We would expect some financials soon.
There are 6 million pregnancies in the United States alone every year. If BPAC can capture 2% market share with an average $60.00 worth of product sold. That is 7.2 million in gross revenue. BPAC currently has a 1.2 million market cap. Most companies trade at least 10 times EPS. BPAC could be trading at 10 to 70 times it's current price per share.
From an 8-k filed May 11th 2012: Share structure and BPAC zero debt
Capital. The authorized capital stock of BPAC consists of 50,000,000 shares of Common Stock, $0.001 par value, of which 42,161,104 shares of Common Stock are issued and outstanding, and 10,000,000 shares of Preferred Stock, par value $0.001, of which 2,330,000 are issued and outstanding (620,000 shares of Series A Convertible Preferred Stock, 1,000,000 shares of Series B Convertible Preferred Stock, and 710,000 shares of Series C Preferred Stock) All outstanding shares are fully paid and non-assessable, free of liens, encumbrances, options, restrictions and legal or equitable rights of others not a party to this Agreement. At the Closing, other than as listed on Schedule 2.02, there will be no outstanding subscriptions, options, rights, warrants, convertible securities, or other agreements or commitments obligating BPAC to issue or to transfer from treasury any additional shares of its capital stock. None of the outstanding shares of BPAC are subject to any stock restriction agreements.
Barchart.com lists BPAC as a 96% buy recommendation.
Check out our websites new look and theme and read our new disclaimer, all alerts are 100% uncompensated.
Recent winners: ATRN 3600% , AUCI 200%, AXLX 300%, BBRD 100%
THANK YOU,
The Team at FPP
